Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | GABRP | O00591 | 1/20 | 0.51 |
| ▸ | GABRD | O14764 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.51 |
| ▸ | GABRE | P78334 | 1/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29593629 | 1.00 | CYP2A6 (0.58) | CYP2A6ALDH1A1KDM4EMAPTIMPDH2 | |
| SCHEMBL2535253 | 0.87 | GABRP (0.60) | CYP2A6ALDH1A1KDM4EMAPTIMPDH2 | |
| SCHEMBL30665978 | 0.87 | GABRP (0.60) | CYP2A6ALDH1A1KDM4EMAPTIMPDH2 | |
| SCHEMBL4352262 | 0.80 | TDO2 (0.63) | ALDH1A1KDM4EMAPTIDO1CYP1A2 | |
| SCHEMBL4352266 | 0.80 | TDO2 (0.63) | ALDH1A1KDM4EMAPTIDO1CYP1A2 | |
| SCHEMBL2557797 | 0.78 | GABRP (0.53) | CYP2A6ALDH1A1KDM4EMAPTIMPDH2 | |
| SCHEMBL2536845 | 0.78 | FBP1 (0.50) | CYP2A6ALDH1A1MAPTGABRPGABRD | |
| SCHEMBL2536847 | 0.78 | FBP1 (0.50) | CYP2A6ALDH1A1MAPTGABRPGABRD | |
| SCHEMBL30487726 | 0.78 | FBP1 (0.50) | CYP2A6ALDH1A1MAPTGABRPGABRD | |
| SCHEMBL29935657 | 0.77 | PIM3 (0.65) | CYP2A6ALDH1A1KDM4EMAPTIMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025087365-A1 | METTL3 INHIBITOR | 杭州邦顺制药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20240002339-A1 | THERAPEUTIC COMPOUNDS AND METHODS | NATIONAL INSTITUTES OF HEALTH | 2024-01-04 | — | — | US | disclosed |
| EP-4204808-A1 | TARGET ENGAGEMENT ASSAY FOR RAS PROTEINS | Promega Corporation (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116391129-A | Target binding assays for RAS proteins | 普罗美加公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| CN-114213396-B | Indole-2-ketone compound and preparation method and application thereof | 深圳市乐土生物医药有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| WO-2005066132-A1 | THERAPEUTIC AGENTS I | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-6822100-B2 | REACTING N-SULFONYL-3-VINYLINDOLE WITH RUTHENIUM COMPLEX IN PRESENCE OF ETHYL DIAZOACETATE AND TOLUENE; PSYCHOLOGICAL, SEXUAL, AND EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-23 | — | — | US | disclosed |
| US-6777437-B2 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS. SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | MATTSON RONALD J (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1373203-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | disclosed |
| WO-2002079152-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002339-A1 | THERAPEUTIC COMPOUNDS AND METHODS | CDK2, CDK1, CCNI | CYP2A6 3813/4885ALDH1A1 3926/4885KDM4E 1446/4885 |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885ALDH1A1 4369/4885KDM4E 171/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | CYP2A6 202/4885ALDH1A1 1218/4885KDM4E 1970/4885 |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR1A, HTR1D, TPH1 | CYP2A6 255/4885ALDH1A1 516/4885KDM4E 3636/4885 |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR5A, HTR1A, HTR2C | CYP2A6 287/4885ALDH1A1 961/4885KDM4E 2977/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | CYP2A6 2040/4885ALDH1A1 3877/4885KDM4E 1948/4885 |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP2A6 4370/4885ALDH1A1 4369/4885KDM4E 171/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CYP2A6 3717/4885ALDH1A1 4277/4885KDM4E 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.